|
US9273283B2
(en)
*
|
2009-10-29 |
2016-03-01 |
The Trustees Of Dartmouth College |
Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
|
|
SG11201505896YA
(en)
|
2013-02-20 |
2015-09-29 |
Novartis Ag |
Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
|
|
ES2769574T3
(es)
|
2013-03-15 |
2020-06-26 |
Michael C Milone |
Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva
|
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
|
WO2015090229A1
(en)
|
2013-12-20 |
2015-06-25 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
|
EP3097117B1
(en)
|
2014-01-21 |
2023-10-04 |
Novartis Ag |
Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
|
|
JP6831777B2
(ja)
|
2014-07-21 |
2021-02-17 |
ノバルティス アーゲー |
Ｃｄ３３キメラ抗原受容体を使用する癌の処置
|
|
AU2015292744C1
(en)
|
2014-07-21 |
2021-01-21 |
Novartis Ag |
Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
|
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
EP3712171A1
(en)
|
2014-08-19 |
2020-09-23 |
Novartis AG |
Treatment of cancer using a cd123 chimeric antigen receptor
|
|
US11459390B2
(en)
|
2015-01-16 |
2022-10-04 |
Novartis Ag |
Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
|
|
WO2016126608A1
(en)
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
PL3280729T3
(pl)
|
2015-04-08 |
2022-08-22 |
Novartis Ag |
Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19
|
|
WO2016168595A1
(en)
|
2015-04-17 |
2016-10-20 |
Barrett David Maxwell |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
|
WO2016172583A1
(en)
|
2015-04-23 |
2016-10-27 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
US10829735B2
(en)
|
2015-07-21 |
2020-11-10 |
The Trustees Of The University Of Pennsylvania |
Methods for improving the efficacy and expansion of immune cells
|
|
US11667691B2
(en)
|
2015-08-07 |
2023-06-06 |
Novartis Ag |
Treatment of cancer using chimeric CD3 receptor proteins
|
|
WO2017040930A2
(en)
|
2015-09-03 |
2017-03-09 |
The Trustees Of The University Of Pennsylvania |
Biomarkers predictive of cytokine release syndrome
|
|
WO2017093969A1
(en)
|
2015-12-04 |
2017-06-08 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
EP3432924A1
(en)
|
2016-03-23 |
2019-01-30 |
Novartis AG |
Cell secreted minibodies and uses thereof
|
|
JP7467117B2
(ja)
|
2016-10-07 |
2024-04-15 |
ノバルティス アーゲー |
癌の治療のためのキメラ抗原受容体
|
|
US11535662B2
(en)
|
2017-01-26 |
2022-12-27 |
Novartis Ag |
CD28 compositions and methods for chimeric antigen receptor therapy
|
|
KR20190130608A
(ko)
|
2017-03-22 |
2019-11-22 |
노파르티스 아게 |
면역종양학을 위한 조성물 및 방법
|
|
SG11202003415XA
(en)
|
2017-10-18 |
2020-05-28 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
WO2019136432A1
(en)
|
2018-01-08 |
2019-07-11 |
Novartis Ag |
Immune-enhancing rnas for combination with chimeric antigen receptor therapy
|
|
IL279367B2
(en)
|
2018-06-13 |
2026-05-01 |
Novartis Ag |
BCMA chimeric antigen receptors and their uses
|
|
SI3844267T1
(sl)
|
2018-08-31 |
2025-10-30 |
Novartis Ag |
Postopki izdelave celic, ki izražajo receptorje himernega antigena
|
|
CN109517073A
(zh)
*
|
2018-11-30 |
2019-03-26 |
北京泽勤生物医药有限公司 |
一种靶向治疗肿瘤的融合肽及其应用
|
|
WO2020122104A1
(ja)
*
|
2018-12-11 |
2020-06-18 |
国立大学法人京都大学 |
ゲノムｄｎａに欠失を誘導する方法
|
|
WO2020206055A1
(en)
*
|
2019-04-02 |
2020-10-08 |
Yale University |
Methods of treatment of diseases and disorders associated with increased tet level, increased h19 level, increased level of tgf signaling, or any combination thereof
|
|
MX2021013218A
(es)
|
2019-05-01 |
2021-12-10 |
Pact Pharma Inc |
Composiciones y metodos para el tratamiento del cancer usando una terapia con celulas t modificadas con tet2.
|
|
PH12022550548A1
(en)
|
2019-09-06 |
2023-11-20 |
Crispr Therapeutics Ag |
Genetically engineered t cells having improved persistence in culture
|
|
JP7805928B2
(ja)
|
2019-11-26 |
2026-01-26 |
ノバルティス アーゲー |
Ｃｄ１９及びｃｄ２２キメラ抗原受容体及びその使用
|
|
WO2021108661A2
(en)
|
2019-11-26 |
2021-06-03 |
Novartis Ag |
Chimeric antigen receptors and uses thereof
|
|
EP4076476A4
(en)
*
|
2019-12-17 |
2023-11-22 |
The General Hospital Corporation |
MODIFIED IMMUNE CELLS WITH REDUCED TOXICITY AND THEIR USES
|
|
US12685490B2
(en)
|
2020-01-28 |
2026-07-21 |
The Board Of Trustees Of The Leland Stanford Junior University |
Method of preventing or treating pancreatic dysfunction or diabetes by upregulating human cathelicidin LL-37 to inhibit islet amyloid polypeptide (IAPP) self-assembly
|
|
CN115427451B
(zh)
*
|
2020-02-14 |
2026-02-17 |
北京永泰瑞科生物科技有限公司 |
过表达从外部导入的细胞信号调节因子的免疫细胞及其用途
|
|
US20230355671A1
(en)
*
|
2020-03-18 |
2023-11-09 |
The Board Of Trustees Of The Leland Stanford Junior University |
Upregulation of Cathelicidin Gene Expression as an Adjuvant to Other Treatments for Diseases
|
|
EP4168451A2
(en)
|
2020-06-22 |
2023-04-26 |
NGM Biopharmaceuticals, Inc. |
Lair-1-binding agents and methods of use thereof
|
|
WO2022040586A2
(en)
|
2020-08-21 |
2022-02-24 |
Novartis Ag |
Compositions and methods for in vivo generation of car expressing cells
|
|
EP4501951A3
(en)
*
|
2020-08-25 |
2025-04-30 |
Kite Pharma, Inc. |
T cells with improved functionality
|
|
CN113234169B
(zh)
|
2020-12-11 |
2022-11-01 |
广州百暨基因科技有限公司 |
靶向cll1嵌合抗原受体及其应用
|
|
CN113045658B
(zh)
|
2020-12-11 |
2021-12-24 |
广州百暨基因科技有限公司 |
抗cll1抗体及其应用
|
|
US20240325535A1
(en)
*
|
2021-11-11 |
2024-10-03 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods comprising car t cells comprising prdm1 and/or nr4a3 knockout
|
|
KR102521500B1
(ko)
*
|
2021-12-02 |
2023-04-14 |
한국화학연구원 |
증진된 효능을 갖는 면역세포
|
|
CN114350665A
(zh)
*
|
2022-01-19 |
2022-04-15 |
上海优替济生生物医药有限公司 |
IFN-γ抑制剂及其用途
|
|
CN114404592A
(zh)
*
|
2022-02-09 |
2022-04-29 |
复旦大学附属中山医院 |
Tet2作为靶标在治疗缺血性血管疾病中的应用
|
|
US20260083844A1
(en)
*
|
2022-09-15 |
2026-03-26 |
H. Lee Moffitt Cancer Center And Research Institute Inc. |
Downregulating inos to increase car-t killing
|
|
WO2025189025A2
(en)
*
|
2024-03-07 |
2025-09-12 |
Biontech Us Inc. |
Methods and compositions for engineering t cells
|